Reports
Sale
Global Radiopharmaceutical Theranostics Market Size, Trends: By Product Type: Alpha Emitters, Beta Emitters, Positron Emission Tomography (PET) Tracers; By Radioisotope: Technetium-99, Gallium-68, Iodine-131, Iodine-123, Others; By Source; By Applications; By Indications; By End User; Regional Analysis; Supplier Landscape; 2024-2032
Global Radiopharmaceutical Theranostics Market Outlook
The global radiopharmaceutical theranostics market size reached a value of around USD 2.73 billion in 2023, driven by the increasing prevalence of cancer and increasing demand for precision medicine. The market is further expected to grow at a CAGR of 13.8%.
Radiopharmaceutical Theranostics: Introduction
Radiopharmaceutical theranostics – the word theranostics is a combination of two words therapeutics and diagnosis, which is achieved with the help of radioisotopes. This involves the utilisation of radiopharmaceuticals labelled with radioactive isotopes, which when goes in patient’s body and helps in tracing the location of the tumour through diagnostic imaging. Administration of small amounts of radioisotopes helps in determining structure, function, metabolism of organs, and tissues within the body. The rising application of radiopharmaceutical theranostics in the diagnostic process has been aiding the radiopharmaceutical theranostics market growth.
After tracing the disease location, same or different radioactive isotopes can be utilized for delivering the therapeutic dose of radiation, which is also called as targeted therapy. The radiation emitted helps in destruction of diseased cells while minimizing the impact on healthy cells. Radiopharmaceutical theranostics finds wide applications in cancer treatment.
Global Radiopharmaceutical Theranostics Market Analysis
Based on segments, the market is divided into product type, radioisotopes, source, applications, indications, end users and region.
Market Breakup by Product Type
- Alpha Emitters
- Beta Emitters
- Positron Emission Tomography (PET) Tracers
Market Breakup by Radioisotopes
- Technetium-99
- Gallium-68
- Iodine-131
- Iodine-123
- 18F
- Y-90
- Lutetium (Lu) 177
- Copper (Cu) 67
- Copper (Cu) 64
- Others
Market Breakup by Source
- Nuclear Reactors
- Cyclotrons
Market Breakup by Applications
- Targeted Therapeutic
- Companion Diagnostic
- Others
Radiopharmaceutical Theranostics Market Segmentation by Indications
- Oncology
- Cardiology
- Neurology
- Others
Market Breakup by End Users
- Hospitals
- Diagnostic Imaging Centres
- Academic and Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Radiopharmaceutical Theranostics Market Overview
The market growth is driven by the increasing prevalence of cancer worldwide. Cancer treatment requires the detection of tumours location and provision of therapy to the target site, which is the function of radiopharmaceuticals. Radiopharmaceuticals help in the detection of the abnormalities and provide targeted therapy to that area by destruction of diseased cells, while minimizing the impact on healthy cells through radiations. Growth of the healthcare sector is directly proportional to the demand of advanced treatments and diagnostics. The rapidly advancing technologies in the healthcare system significantly contribute to the radiopharmaceutical theranostics market demand.
With the advances in technology, the efficacy, accuracy, and sensitivity of the imaging technology have also increased, which helps in better diagnosis of the disease. Increasing demand of precision medicine is responsible for the growth of this market as radiopharmaceutical theranostics is tailor-made for each patient.
Based on regions, North America accounts for a significant radiopharmaceutical theranostics market share due to the rising prevalence of cancer and other tumour diseases. The demand for diagnostics is rising with the rising prevalence of these disorders. The dominance of the region can also be attributed to the rising mergers and acquisitions amongst the leading players to develop more advanced ad efficient products.
Competitive Landscape
The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model, along with giving a SWOT analysis. The report gives a detailed analysis of the following radiopharmaceutical theranostics companies, covering their competitive landscape and the latest developments like mergers, acquisitions, investments, and expansion plans.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- Novartis AG
- Aurobindo Pharma
- Bayer AG
- Blue Earth Diagnostics
- Cardinal Health
- Clarity Pharmaceuticals
- GE Healthcare
- Jubliant Radiopharma
- Navidea Biopharmaceuticals, Inc.
- SOFIE
- Telix Pharmeceuticals
- Lantheus Medical Imaging
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product Type |
|
| Breakup by Radioisotope |
|
| Breakup by Source |
|
| Breakup by Applications |
|
| Breakup by Indications |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Radiopharmaceutical Theranostics Market Overview
3.1 Global Radiopharmaceutical Theranostics Market Historical Value (2017-2023)
3.2 Global Radiopharmaceutical Theranostics Market Forecast Value (2024-2032)
4 Global Radiopharmaceutical Theranostics Market Landscape
4.1 Global Radiopharmaceutical Theranostics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Radiopharmaceutical Theranostics Product Landscape
4.2.1 Analysis by Product Type
4.2.2 Analysis by Application
5 Global Radiopharmaceutical Theranostics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Radiopharmaceutical Theranostics Market Segmentation
6.1 Global Radiopharmaceutical Theranostics Market by Product Type
6.1.1 Market Overview
6.1.2 Alpha Emitters
6.1.3 Beta Emitters
6.1.4 Positron Emission Tomography (PET) Tracers
6.2 Global Radiopharmaceutical Theranostics Market by Radioisotope
6.2.1 Market Overview
6.2.2 Technetium-99
6.2.3 Gallium-68
6.2.4 Iodine-131
6.2.5 Iodine-123
6.2.6 18F
6.2.7 Y-90
6.2.8 Lutetium (Lu) 177
6.2.9 Copper (Cu) 67
6.2.10 Copper (Cu) 64
6.2.11 Others
6.3 Global Radiopharmaceutical Theranostics Market by Source
6.3.1 Market Overview
6.3.2 Nuclear Reactors
6.3.3 Cyclotrons
6.4 Global Radiopharmaceutical Theranostics Market by Applications
6.4.1 Market Overview
6.4.2 Targeted Therapeutic
6.4.3 Companion Diagnostic
6.4.4 Others
6.5 Global Radiopharmaceutical Theranostics Market by Indications
6.5.1 Market Overview
6.5.2 Oncology
6.5.3 Cardiology
6.5.4 Neurology
6.5.5 Others
6.6 Global Radiopharmaceutical Theranostics Market by End User
6.6.1 Market Overview
6.6.2 Hospitals
6.6.3 Diagnostic Imaging Centers
6.6.4 Academic and Research Institutes
6.6.5 Others
6.7 Global Radiopharmaceutical Theranostics Market by Region
6.7.1 Market Overview
6.7.2 North America
6.7.3 Europe
6.7.4 Asia Pacific
6.7.5 Latin America
6.7.6 Middle East and Africa
7 North America Radiopharmaceutical Theranostics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Radiopharmaceutical Theranostics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Radiopharmaceutical Theranostics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Radiopharmaceutical Theranostics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Radiopharmaceutical Theranostics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Novartis AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisition
17.1.5 Certifications
17.2 Aurobindo Pharma
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisition
17.2.5 Certifications
17.3 Bayer AG
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisition
17.3.5 Certifications
17.4 Blue Earth Diagnostics
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisition
17.4.5 Certifications
17.5 Cardinal Health
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisition
17.5.5 Certifications
17.6 Clarity Pharmaceuticals
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisition
17.6.5 Certifications
17.7 GE Healthcare
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisition
17.7.5 Certifications
17.8 Jubliant Radiopharma
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisition
17.8.5 Certifications
17.9 Navidea Biopharmaceuticals, Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisition
17.9.5 Certifications
17.10 SOFIE
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisition
17.10.5 Certifications
17.11 Telix Pharmeceuticals
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisition
17.11.5 Certifications
17.12 Lantheus Medical Imaging
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisition
17.12.5 Certifications
18 Global Radiopharmaceutical Theranostics Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of USD 2.73 billion in 2023, driven by the increasing prevalence of cancer, advancements in imaging technology, increasing research and development, and increasing demand for precision medicine.
The market is anticipated to grow at a CAGR of 13.8% during the forecast period of 2024-2032 to attain a value of around USD 8.74 billion by 2032.
The growth of the market is driven by the increasing prevalence of cancer, advancements in imaging technology, increasing research and development, and increasing demand for precision medicine.
The key trends which are bolstering the market growth include personalized medicine and diagnostics, increasing adoption of targeted therapies, growing research and developments and development of new radiopharmaceuticals.
The major product types are alpha emitters, beta emitters, and positron emission tomography (pet) tracers.
The major radioisotopes in the market include Technetium-99, Gallium-68, Iodine-131, Iodine-123, 18F, Y-90, Lutetium (Lu) 177, Copper (Cu) 67, and Copper (Cu) 64, among others.
The major sources of the product can be categorized into nuclear reactors and cyclotrons.
The major indications include oncology, cardiology, and neurology, among others.
The major applications are targeted therapeutic and companion diagnostic, among others.
The end users of this market are hospitals, diagnostic imaging centres, academic and research institutes, among others.
The major regional markets include North America, Europe, Asia Pacific, Latin America, Middle East, and Africa.
The key players in the market can be categorised into include Novartis AG, Aurobindo Pharma, Bayer AG, Blue Earth Diagnostics, Cardinal Health, Clarity Pharmaceuticals, GE Healthcare, Jubliant Radiopharma, Navidea Biopharmaceuticals, Inc., SOFIE Telix Pharmeceuticals, and Lantheus Medical Imaging.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER